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This review describes the germ cell neoplasms that are malignant and most commonly associated with several
types of gonadal dysgenesis. The most common neoplasm is gonadoblastoma, while others including
dysgerminomas, yolk-sac tumors and teratomas are rare but can occur. The purpose of this review is to
evaluate the incidences of these abnormalities and the circumstances surrounding these specific tumors.
According to well-established methods, a PubMed systematic review was performed, to obtain relevant studies
published in English and select those with the highest-quality data.
Initially, the first search was performed using gonadal dysgenesis as the search term, resulting in 12,887 PubMed
papers, published, from 1945 to 2017. A second search using ovarian germ cell tumors as the search term
resulted in 10,473 papers, published from 1960 to 2017. Another search was performed in Medline, using germ
cell neoplasia as the search term, and this search resulted in 7,560 papers that were published between 2003 to
2016, with 245 new papers assessing gonadoblastomas.
The higher incidence of germ cell tumors in gonadal dysgenesis is associated with a chromosomal anomaly that
leads to the absence of germ cells in these gonads and, consequently, a higher incidence of neoplasms when
these tumors are located inside the abdomen. Several hypotheses suggest that increased incidence of germ cell
tumors involves all or part of the Y chromosome or different genes.
KEYWORDS: Ovarian Neoplasms; Gonadal Dysgenesis; Gonadal Neoplasms; Gonadoblastoma; Germ Cells
Tumors; Dysgerminoma; Teratoma; Yolk-sac Tumor.
’ INTRODUCTION
Germ cell tumors (GCTs), or germ cell cancers (GCCs) are
a heterogeneous group of ovarian neoplasms that originate,
during different stages of development, from germ cells that
colonize the ovaries or gonads. These specific tumors account
for approximately 15-20% of primary ovarian tumors, 95% of
which are mature cystic teratomas. They predominantly affect
young women and may differ in their clinical, histologically
and biologically presentation and include benign and malign
subtypes. Nearly 60% of ovarian tumors occurring in women
under the age of 21 and less than 5% of ovarian cancers have a
germ cell origin (1).
The risk for the development of GCTs is an important
factor in the management of patients with disorders of sex
development (DSD) (2).
’ METHODS
We performed a PubMed systematic review, to obtain
relevant studies that were published in English and select
those with the highest-quality scientific data.
The first search was performed using gonadal dysgenesis
as the search term, resulting in 12,887 papers in PubMed,
published from 1945 to 2017. The second search using ovarian
GCTs as the search term resulted in 10,473 papers, published
from 1960 to 2017.
Other papers describing GCTs were as follows: gonado-
blastomas, published between 1953 and 2017 (790 papers);
dysgerminomas, published between 1944 and 2017 (2208
papers); teratomas, published between 1913 and 2017 (5573);
and Yolk-sac tumors, published between 1945 and 2017 (756
papers).
Another search was performed with Medline using germ
cell neoplasia as the search term, resulting in 7560 papers
that were published between 2003 and 2016; 245 new papers
on gonadoblastomas were published.
Inclusion criteria: Meta-analyses, systematic reviews and
studies with a large number of patients or with relevant
findings.
Exclusion criteria: Papers that did not meet the above
criteria.
’ GONADAL DYSGENESIS
Gonadal dysgenesis comprises a vast array of clinical
conditions with different somatic and genetic features.
Special attention is necessary because in some of these cases,
neoplasia can develop in dysgenetic gonads (3).
The different classifications for gonadal dysgenesis pro-
posed by the authors of this review are based on the
abnormal differentiation of the gonads, and these classifica-
tions include three categories, presented in Table 1.DOI: 10.6061/clinics/2019/e408
Copyright & 2019 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
Received for publication on April 4, 2018. Accepted for publication
on June 24, 2019
1
REVIEW ARTICLE
Table 2, in 2006, the Chicago consensus meeting on the
management of the DSD classification was established and
revised by Hughes et al. (4).
In genetic females or individuals presenting with X
chromosome monosomy, the ovaries do not undergo
complete differentiation and these undifferentiated gonads
are similar to a white ‘‘conjunctive streak’’, usually having no
endocrine function or gamete production (5).
This newly recognized ‘‘undifferentiated gonadal tissue’’
has been demonstrated to be a gonad with a high risk for
the development of a tumor, including gonadoblastoma and
other tumor types.
Here, we analyze this condition in different groups and
determine the groups that present a greater risk for develop-
ing neoplasia in their dysgenetic gonads.
’ GONADAL DYSGENESIS AND SOMATIC
ABNORMALITIES
Turner syndrome was previously described by Turner (6)
as a distinct entity, with clinical manifestations including the
‘‘stigmas’’ that are pathognomonic of this entity and a hormonal
analysis indicating hypergonadotropic hypogonadism.
Genetic analysis reveals a karyotype of 45,X in 60% of
cases but other chromosomal abnormalities might be
detected, including mosaicisms associated with the 45,X cell
lineage; 45,X/46,XX cell lineage; or 45,X/47,XXX cell lineage.
On the other hand, karyotype analysis is crucial for deter-
mining whether or not the Y chromosome is present, and
whether or not the chromosome is complete or structurally
abnormal, containing deletions such as 45,X/46,X(Yq) or 45,
X/46,Xi(Yp) (7).
Lippe described how germ cells usually migrate to the
germinal ridges of the embryo until the third month of
gestation. From this point, a degeneration process occurs,
resulting in the elimination of germ cells and concurrently
accelerating the fibrosis process of the gonadal stroma (5). In
45,X monosomy (Turner syndrome), there is normal ovarian
development at the beginning of fetal life followed by a rapid
loss of germ cells beginning at the 22nd week of gestation,
resulting in a streaked gonad around the time of delivery (8).
This abnormality in gonadal organogenesis is associated
with a greater risk for developing neoplasia in the dysgenetic
gonads (9).
Pure Gonadal Dysgenesis
Hormonal analysis also consists of a hypergonadotropic
hypogonadism entity with conjunctive-streak gonads and a
46,XX or 46,XY karyotype.
These patients have a female phenotype with normal
Mullerian structures but are considered infantile due to their
lack of adequate hormonal stimulation.
The 46,XX form of pure gonadal dysgenesis results from a
gene mutation, which is classified as an autosomal recessive
disorder.
Therefore, Swyer’s description of the 46,XY form of pure
gonadal dysgenesis is clinically identical to the previous
description. Here, dysgenetic gonads are at a 30% risk of
developing a neoplasia, such as gonadoblastoma or dysger-
minoma (2).
The potential genetic etiology the Swyer form is due to an
autosomal gene disorder, with recessive or dominant fea-
tures, but is restricted to males (10).
Previous studies by Verp and Simpson et al., Scherer et al.
and Assumpc¸ão et al. reported that 10-15% of cases of
this gonadal dysgenesis are attributed to a mutation or
deletion in SRY, but 70-80% of cases are of unknown etiology
(9,11,12).
Mixed Gonadal Dysgenesis
Mixed gonadal dysgenesis a rare disorder characterized
primarily by a dysgenetic streaked gonad on one side and a
potentially undifferentiated testicle on the other (13).
Therefore, Mullerian structures develop on one side and
are inhibited by the presence of anti-Mullerian hormone
(AMH) that is produced by the Sertoli cells of the testicle.
The external genitals are subject to variable levels of
androgenization, which depend on testicular androgen activity.
A wide variety of clinical manifestations can occur, ranging
from male external genitalia with varying degrees of hypos-
padias, to ambiguous or even female genitalia (14).
Mixed gonadal dysgenesis (MGD) is also known as asym-
metric or atypical gonadal dysgenesis, and genetic studies
have revealed a karyotype of 45,X/46,XY mosaicism.
Table 1 - Proposed criteria for the classification of gonadal
dysgenesis.
1. Male Phenotype Klinefelter Syndrome. 47,XXY or Similar
2. Female Phenotype a - Gonadal Dysgenesis with Somatic
Abnormalities: 45,X or Similar




Mixed Gonadal Dysgenesis: 46,XY/45,X
Denys-Drash Syndrome: 46,XY
Table 2 - Classification of disorders of sex development (modified from Hughes et al. 2006) (4).
Sex chromosomal DSD 46,XY DSD 46,XX DSD
45,X Turner syndrome Testicular GD Ovarian GD
47,XXY Klinefelter syndrome Complete GD Ovotesticular DSD
45,X/46,XY and variants Partial GD Testicular DSD
46,XX/46,XY and variants Gonadal regression Androgen excess
Ovotesticular DSD Fetal level CAH
Disorder of androgen Aromatase deficit
Biosynthesis/action Maternal ovary tumor
LH receptor defect Fetal adrenal tumor
Defective action AMH Other: cloacal extrophy
or AMH receptor Severe epispadias
Other: cloacal exstrophy Mayer-Rokitansky-Kuster-Hauser syndrome
Severe hypospadias
AMH=Anti-Mullerian hormone CAH=Congenital adrenal hyperplasia
DSD=Disorder of sex development GD=Gonadal dysgenesis
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Turner syndrome ‘‘stigmas’’ can be frequently found among
these patients (13). In previous studies, Verp et al., Alvarez-
Nava et al., and Mendez et al. reported that dysgenetic gonads
or even dysgenetic testicles are at a greater risk for developing
neoplasia (9,13,14).
Denys-Drash Syndrome
Denys-Drash syndrome is a condition that is characterized
by a typical male chromosome pattern (46,XY), renal failure
and Wilms tumors, whereas the external genitalia range from
ambiguous to completely female or completely male (15).
Dysgenetic gonads or rudimentary and immature testes
can be observed. Therefore, the internal genitals of affected
individuals can develop Wolffian or Mullerian structures.
The short arm of chromosome 11 from the 11p13 chromo-
somal region harbors the WT1 tumor suppressor gene, which
was previously reported to be the oncogene hypothesized
to result in Wilms tumors (16). As a result, there is also a
greater risk for developing gonadal tumors, such as
gonadoblastoma.
’ GONADAL TUMORS
Abnormalities in gonadal development are triggering
factors for the development of neoplasia in dysgenetic
gonads. A variety of different tumors can develop, and
these tumors are frequently classified as germinal tumors,
also known as GCCs (17). The malignant germ cell tumor is
a complication that can occur in patients with a DSD. The
development of tumors in an individual depends on a
number of genetic or epigenetic factors related to early
gonadal and germ cell development and possibly correlates
with genetic susceptibility.
Gonadal GCTs are histologically subdivided into semino-
matous and nonseminomatous tumors. The seminomatous
tumors are composed of neoplastic cells that are arranged
in a similar manner to embryonic germ cells or gonocytes,
and these tumors are classified as dysgerminomas in the
ovary or dysgenetic gonad, as seminomas in the testis and as
germinomas in extragonadal localizations. Nonseminoma-
tous neoplasia comprises different types of tumors including
teratomas, yolk-sac tumors, choriocarcinomas and embry-
onal carcinomas (18,19). The gonadoblastoma is the pre-
cursor to the invasive germ cell tumor, predominantly
dysgerminoma, in the dysgenetic gonads.
Gonadoblastoma
Gonadoblastoma is a mixed germ cell tumor with undif-
ferentiated cells and is most frequently observed in female
children, 1/3 of whom are younger than 15 years of age. This
tumor was first described by Scully (20). It is most commonly
found on the right gonad, although it has been frequently
detected on both sides (21). This tumor is regarded as an in
situ type of germ cell tumor in dysgenetic gonads and is a
precursor to seminoma/dysgerminoma tumors (22).
Affected patients present with delayed puberty with some
virilization as a result of androgen production. Tumors can
grow from histological lesions up to a maximum of 8 cm.
Most of them measure between 1 and 5 cm, but a consi-
derable proportion are microscopic in size. A suspicious case
can be confirmed by the presence of microcalcifications in the
gonads (20).
Histologically, this neoplasia consists of a tumor composed
of two cell lineages, namely, germ cells that are similar to
dysgerminoma cells and sex cord cells that are similar to
immature Sertoli cells or granulosa cells. The stromal tumor
may also carry cell nests that are similar to Leydig cells and
that contain Reinke crystalloids. Such cell ‘‘nests’’ are usually
small, solid, and oval or round-shaped, and may have inner
calcifications. Because of this mixture of a germ cell tumor
and undifferentiated cells, 60% of gonadoblastoma cases can
result in or be associated with other types of neoplasms, such
as dysgerminomas, although gonadoblastomas are benign
tumors that do not metastasize (23,24). Pure gonadoblasto-
mas are regarded as an in situ type of germ cell tumor that
affects patients with dysgenetic gonads.
Scully reported that the Y chromosome found in the
karyotypes of affected patients was the triggering factor for
the development of gonadal neoplasia (25).
Specific loci from genes identified at the Y chromosome are
considered to be the trigger for the development of tumors.
These genes are probably located in the short arm of this
chromosome, within its centromere (26).
In 1987, Page postulated that there was a gonadoblastoma
locus on the Y chromosome, which was located near the
centromere or on its long arm (27). Tsuchiya et al. and Salo et
al. detected a small and distinct region within the centromere
of the Y chromosome with an estimated size of 1-2 Mb
(26,28). The testis-specific protein, Y-encoded (TPSY) gene,
which is located within the gonadoblastoma locus on the
Y chromosome, has been shown to be involved in the
numerous transformation processes of germ cells (28).
The identification of these genetic markers in the Y
chromosome is an important predictor of future neoplasm
development.
Bagnoli et al. and Piazza et al. have previously described
the incidence of neoplasms in dysgenetic gonads, revealing
their concern in view of this perspective (3,21). Patients with
gonadoblastoma without dysgerminoma or another germ
cell tumor are treated only by surgical excision of the gonads
without any additional therapy. However, if dysgerminoma
or another tumor is present, surgical staging and post-
operative combination chemotherapy with bleomycin, ecto-
poside and cisplatin may be required (29).
The true incidence of gonadal GCTs in children is
unknown, and few studies have been published on the
incidence of this tumor in pediatric populations. When the
correct diagnosis and proper treatment occur during the
early stage, most gonadal tumors are curable (30).
Bianco et al. observed that SRY or OCT4 gene expression
increased the risk of developing gonadoblastoma, even in
patients with Turner syndrome (31-33). De Marqui et al.
observed and described the prevalence of the Y chromosome
with gonadoblastoma in Turner syndrome, and molecular
analysis to determine Y chromosome sequences in Turner
syndrome is indicated, regardless of karyotype (34).
Dysgerminoma
Dysgerminoma is a malignant tumor that is driven by
the proliferation of primitive germ cells associated with
conjunctive tissue septum. It is the second most common
neoplasm associated with gonadoblastoma or that develops
in dysgenetic gonads. This tumor is identical to testicular
seminoma and is frequently diagnosed in the second decade
of life (35).
Macroscopically, these are well-encapsulated and unilat-
eral tumors in 90% of cases. Ten percent of cases have
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contralateral involvement, and another 10% of cases have
occult involvement that can only be detected through
biopsies (36).
Histological analysis reveals the proliferation of germ
cells with a polygonal or oval shape, which linked to chords
with a vacuous, abundant and pale cytoplasm. Chronic T
lymphocyte infiltration is also present, and a variable mitotic
rate, as well as anisokaryosis rate, define the degree of
malignancy (37).
No factors have been associated with the etiology of
dysgerminoma, apart from an increased incidence associated
with dysgenetic gonads. A total of 5% of dysgerminomas
are associated with cytogenetic abnormalities involving all
or part of the Y chromosome or MGD, namely, 45,X/46,XY
(34,38).
Capito et al. have reported the rare occurrence of this
tumor in association with gonadoblastoma in 6 children,
who were approximately 11 years of age, presenting with
pure gonadal dysgenesis and the 46,XY karyotype (37).
Tumoral behavior, regardless of whether or not trophoblastic
tissue producing human chorionic gonadotropin (hCG) is
present, requires further examination and follow up. Other
references that relate dysgerminomas to gonadoblastomas
have been reported by Yilmaz et al., Maleki et al., Talerman
et al., and Subbiah et al. with descriptions of several
anatomopathological, chromosomal and gene anomalies
(23,24,35,38). At the time of surgical operation, this neoplasm
is found to have spread locally in 20 to 30% of cases. The
main route of dissemination is through regional lymphatics,
and the most commonly involved lymph nodes are the
retroperitoneal, paraaortic and mediastinal lymph nodes.
Bony metastases may occur in the sacral, lumbar or dorsal
vertebrae (39).
Brody analyzed the factors that affect patient survival and
concluded that the five-year survival rate was 95% if the
tumor was encapsulated and movable, 75% if adhesions
were present, 60% if rupture of the tumor capsule occurred,
and only 33% if metastases were detected (40). Most
recurrences are found in the first two years after the primary
operation, and the recurrence rate depends on the extent of
the lesion and the type of therapy (36).
Endodermal Sinus Tumor
The endodermal sinus tumor is a morphologically hetero-
geneous tumor and is, also known as a yolk-sac tumor. The
endodermal sinus tumor arises from endodermal structures
and is characterized by alpha-fetoprotein production and
its highly malignant nature. Among other indicators, the
malignant nature of this tumor serves as an epithelial cell
lining marker for these tumors (41).
These tumors are relatively well-encapsulated tumors, that
are gray in color, have a soft consistency, and have central
necrotic areas, and the largest diameters of these tumors vary
from 8-25 cm (42).
Histological analysis shows reticular features with arbor-
escent-like stromal tissue that includes several degrees of
atypia, with Schiller-Duval bodies considered pathognomo-
nic of this neoplasm (43).
Positive cytokeratin tests can differentiate solid yolk-sac
tumors from dysgerminomas (43).
This neoplasm may manifest in childhood when it has
a soft consistency and is more sensitive to chemotherapy.
During adulthood, tumors have a mixed appearance and a
less favorable chemotherapeutic response (30). These tumors
can be found either on dysgenetic gonads or on other body
parts, such as the testes, vagina, ovaries, urachus, retro-
peritoneum, or mediastinum. Cytogenetic analysis revealed
the increased incidence of this neoplasm in isochromosome
i(12p) or in 1p36 deletions (44). Likewise, it was observed
that the loss of RUNX3 gene located at chromosome 1p36.1
triggered tumor development, since this gene serves as a
tumor suppressing agent (45).
Ito & Kawamata, Madiwale et al., Nam et al., Riopel et al.
and Looijenga et al. previously described this neoplasm in
patients with gonadal dysgenesis (44-48). Nasioudis et al.
analyzed 561 women with this neoplasia and determined
that the median age was 23 years and that the majority of
tumors, namely, 58.5%, were stage I or stage II disease, while
29.6% and 11% of tumors were stage III and stage IV disease,
respectively. These patients were treated by hysterectomy,
lymphadenectomy and omentectomy, and those who received
chemotherapy achieved an increased survival rate compared
with the group that did not receive chemotherapy (30).
Other neoplasms, including teratomas and juvenile gran-
ulosa cell tumors, have also been described as potential
gonadal dysgenesis tumors (48).
Teratomas, commonly known as mature cystic teratomas,
are cystic tumors and consist of a monodermal teratoma
component. Generally arising from the epithelium, these
tumors are frequently referred to as ‘‘dermoid cysts’’ and occur
during the first years of menacme, representing approximately
58% of benign ovarian tumors. Ovarian teratomas are bilateral
in 10-17% of cases, always contain brownish-gray and always
contain greasy material and hairs (49).
Neoplasms that contain other benign tissues can also be
detected, and these neoplasms include teratomas composed
of thyroid tissue, namely, ‘‘struma ovarii’’; carcinoid tumors;
and immature teratomas known as adenomas that produce
corticotrophin or prolactin (50).
These neoplasms represent 3% of all cases and 1% of all
ovarian carcinomas and are often unilateral and solid (50).
Its markers include the beta subunit of hCG, alpha-
fetoprotein (AFP) and plasma T4 (thyroxine). Norris et al.
classified immature teratomas into grades 1, 2 and 3
according to their cell differentiation status (50).
Immature grade 1 or 2 teratomas are diploid in 90% of
cases; immature grade 3 teratomas are aneuploid in 66% of
cases or present other karyotype abnormalities (50).
Embryonal carcinomas or polyembryomas are rare tumors
that can develop simultaneously from the germ cell com-
ponent of gonadoblastomas. Given the wide variety of
hormones produced, its clinical manifestations are numerous
and may include precocious pseudopuberty during child-
hood or abnormal uterine bleeding during menacme (51).
According to Troche & Hernandez, the incidence of such
neoplasms is 9.8% (52).
’ RISKS FACTORS FOR GERM CELL CANCERS
(GCCS) IN DSD PATIENTS
The risk for gonadal GCC development in DSD depends
on a large number of factors that are involved in damage to
the gonads.
The gonadoblastoma-Y (GBY) region is a prerequisite
for gonadoblastoma and is located on the Y chromosome.
A study by Cools et al. hypothesized that a testis-specific
protein encoded by the GBY gene on the Y chromosome may
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have an oncogenic function at high levels (26,28,53,54).
Patients with Turner syndrome have an increased risk of
GCC due to the hidden presence (mosaic) of the GBY region;
additionally, patients with Klinefelter syndrome exhibit early
apoptosis of germ cells, and in Klinefelter syndrome, only the
mediastinum and brain have a high risk for developing an
aggressive GCC (55-57).
This increased risk is determined by the presence of Y
material, mosaicism of the genotype and the degree of
masculinization.
Newer molecular methods permit the detection of Y
chromosome material. FISH and X and Y centromere probes
are sometimes recommended to determine the origin of ring
or small marker chromosomes. Currently, real-time poly-
merase chain reaction with multiple Y specific probes is more
sensitive than the FISH technique and can detect Y
mosaicism in up to 12% of Turner syndrome cases (58).
The rate of gonadoblastoma for Turner syndrome with the
Y chromosome that was detected by PCR or FISH varied
from 4-60% in 14 studies, and when the data are compiled,
the total rate is 10% (59).
Gravholt et al. in 2000 study described a Gonadoblastoma
occurrence in female with Turner syndrome and Y chromo-
some material. In 114 females with phenotype Turner
syndrome were detected 14 (12.2%) who had Y chromosome,
although seven of these patients had a karyotype that did not
suggest the presence of Y chromosome material. In 10 of
these patients the presence of Y material were detected by
PCR with many primers: SRY, ZFY, DYZ, DYS132 and DYZ1.
The risk to develop gonadoblastoma has been estimated to
be larger than 30% (60).
Regarding the localization of the gonads, there are related
small series about the testis. There is a lower incidence of
GCC when the testes are in a normal scrotal position.
Klaassen et al., demonstrated that GCC with a seminoma-
tous histology is more common in undescended testes than
in scrotal testes (61).
Regarding androgen, the absence of androgen receptor
and the presence of complete androgen insensitivity syn-
drome protect against the risk for developing GCC because
of the resulting lack of androgen signaling that leads to
the apoptosis of germ cells and inhibits spermatogenesis, as
concluded by Cools et al. and by O’Shaughnessy et al.
(54,62).
Regarding the genes involved, numerous genes and
transcription factors influence the development of the
urogenital ridge and the testis. Germ cells originate in the
yolk-sac, and migration occurs to develop the urogenital
ridge and the gonads.
OCT4 (octamer-binding-protein), also known as OCT3 or
POU5F1 is a transcription factor with a fundamental function
in the pluripotency of embryonic stem cells and primordial
germ cells. It has been proposed as a marker for GCTs with
pluripotency and is specific to seminoma/dysgerminoma
and embryonal carcinoma (63). Palma et al. analyzed the
utility of OCT3/4, TSPY and beta-catenin as biological
markers for gonadoblastoma formation and malignant GCTs,
and previous results suggested that these markers participate
in important steps during GB malignant transformation (64).
With the development of this method, it became capable of
revealing the increasing level of OCT4 expression in a wide
variety of gonadal and extragonadal GCTs.
The formation of early undifferentiated gonads is regu-
lated by a number of genes, including steroidogenic factor 1
(SF1), Wilms tumor 1 (WT1), and chromobox homolog 2
(CBX2) (65). Ovarian development was thought to be a
passive process that was driven only by the absence of SRY
expression; however, it was recently observed that ovarian
development requires the involvement of WNT family
member 4 (WNT4), Forkhead Box L2 (FOXL2), beta-catenin
1 (CTNNB1), and R-spondin1 (RSPO1) (61). Other markers
have been identified, including SOX17 in seminomas and
SOX2 in embryonal carcinomas (66).
Specific WT1 mutations are capable of causing Denys-
Drash syndrome and Frasier syndrome, with an increased
risk for Wilms kidney tumor and gonadal dysgenesis (15,16).
The Genome wide association studies (GWASs) were used
to identify multiple factors associated with familial testicular
GCC risk including a large number of high risk single
nucleotide polymorphisms whose levels were increased; the
promoter methylation of several genes namely, PDE11A,
SPRY4 and BAK1; and decreased promoter methylation of
KITLG (Stem Cell Factor-c-kit System) (67-69).
Gonadal examination and biopsy must be performed
multiple times to analyze the tissue during gonadectomy or
to postpone the gonadectomy. This is important to balance
the potential risk for GCC or to endocrine and fertility
function.
Histological and immunohistochemical analyses need to
be performed by a pathologist who understands gonadal
development and DSD (70).
’ CONCLUSIONS
We conclude that the higher incidence of GCTs in gonadal
dysgenesis results from the following.
1. Chromosomal gene anomalies that lead to the absence of
germ cells in these gonads and, consequently, a higher
incidence of neoplasms when located inside the abdomen.
The location of this undifferentiated gonadal tissue at a
site with an abnormal temperature can result in metabolic
rate changes and, therefore, an increased risk of develop-
ing neoplasia. Our hypothesis is that mutated genes can
alter the antigen related cell surface in embryonic cells, or
result from a lineage of aneuploid cells arising from germ
cells and that the mutated genes can be tumor suppressor
genes (54).
This undifferentiated gonadal tissue that is found in
dysgenetic gonads would be naturally more susceptible to
the development of neoplasia (70).
2. Together with the centromere and the region near the
long arm of the Y chromosome, a DNA region of 1-2 Mb
coinciding with the GBY region acts as a determinant gene
for tumor growth (26).
3. The prevalence of GCTs is increased in patients with DSD
containing Y chromosome material in their karyotype and
due to the presence the TSPY gene (71).
4. Gonadal biopsy and immunohistochemical biomarkers
(OCT3/4 (POU5F1), TSPY, SOX9, FOXL2 and KITLG
(SCF)) are important to characterize situations in which
GCC development is possible (germ cells tumors) (72).
5. One specific marker for gonadoblastoma and germ cell
neoplasia in situ (GCNIS) is POU5F1, and prolonged
expression of this marker is crucial to GCC development
(73).
6. When all or part of the Y chromosome is detected in these
patients, bilateral gonadectomy must be performed. An
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increased prevalence of GCTs has been noted in indivi-
duals with a Y sequence who have Turner syndrome.
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